Business Blog
1 minute reading time
(27 words)
Biogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapies
The results come amid the rollout of Biogen and Eisai's Leqembi, the first drug found to slow the progression of Alzheimer's to win FDA approval.
Stay Informed
When you subscribe to the blog, we will send you an e-mail when there are new updates on the site so you wouldn't miss them.
Comments